COYA$4.065
Chart
Performance
Key Stats
AI COYA Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
NeutralCoya Therapeutics shows potential in the biotechnology sector, with early-stage clinical progress and a focus on neurodegenerative diseases. However, the company is pre-revenue, highly speculative, and faces significant clinical and regulatory risks. Its current financial position and lack of profitability indicate a high-risk, high-reward profile. Investors should consider the early stage of development and the inherent volatility of clinical-stage biotechs.
Thematic
Coya Therapeutics is positioned within the biotechnology sector, with specific focus on neurodegenerative diseases like ALS, Frontotemporal Dementia, Alzheimer's, and Parkinson's. The growing prevalence of these conditions and advancements in cellular therapies present a significant thematic tailwind.
Fundamental
As a clinical-stage company, Coya Therapeutics has no current revenue or profits. Its financial health is characterized by significant operating expenses and a reliance on external financing. The company's valuation metrics are not applicable in the traditional sense due to the absence of earnings.
Technical
The stock has experienced significant volatility, with a recent upward trend but still trading below its 52-week high. Technical indicators suggest mixed signals, with some positive momentum but also potential resistance levels and caution warranted due to low volume.
| Factor | Score |
|---|---|
| Biotechnology Innovation | 80 |
| Neurodegenerative Disease Market | 85 |
| Cell and Gene Therapy Trends | 70 |
| Regulatory Environment (Biotech) | 65 |
| Collaboration & Partnerships | 75 |
| Factor | Score |
|---|---|
| Valuation | 10 |
| Profitability | 5 |
| Growth | 30 |
| Balance Sheet Health | 50 |
| Cash Flow | 20 |
| Factor | Score |
|---|---|
| Trend Analysis | 50 |
| Momentum | 55 |
| Volume Confirmation | 40 |
| Support & Resistance | 65 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Strong Short-Term Performance
The stock has shown positive performance across multiple short-term periods, with 5D (+17.22%), 1M (+14.02%), and YTD (+16.81%) returns indicating recent upward momentum.
Low Beta
A Beta of 0.26 suggests lower volatility relative to the overall market, which can be attractive for risk-averse investors.
Bearish Points (9)
Negative EPS
The Earnings Per Share (EPS) for the trailing twelve months (TTM) is -$1.07, and recent quarterly EPS estimates are negative, indicating ongoing losses.
High Price-to-Sales Ratio
The Price-to-Sales (PS) ratio is extremely high, with TTM at 429.3 and 2025Q1 at 419.6, suggesting the company's current market valuation is not supported by its current sales and could be a significant risk.
Calendar
Profile
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary therapies to enhance the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as frontotemporal dementia, Alzheimer's disease (AD), and Parkinson's disease. In addition, the company's pre-clinical product candidates include COYA 301, a low-dose interleukin 2 product candidate to treat AD; COYA 303, an investigational biologic combination of COYA 301 and a glucagon-like-peptide-1 receptor agonist for the treatment of inflammatory diseases; COYA 201, an antigen directed Treg-derived exosome product candidate to treat neurodegenerative, autoimmune, and metabolic diseases; COYA 206, an antigen directed Treg-derived exosome product candidate; and COYA 101. It has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. Coya Therapeutics, Inc. was founded in 2020 and is headquartered in Houston, Texas.
Seasonals
Price Target
16.64 USD
The 39 analysts offering 1 year price forecasts for COYA have a max estimate of 20.00 and a min estimate of 14.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Direct competitor in the Amyotrophic Lateral Sclerosis (ALS) market with an FDA-approved drug (RELYVRIO/ALBRIOZA), directly addressing one of COYA's primary therapeutic areas.
Weight: 90
Major pharmaceutical company with a strong focus and established presence in neurodegenerative diseases, including approved therapies for ALS (TOFERSEN), Alzheimer's, and Multiple Sclerosis, offering both competition and a benchmark for neurological drug development.
Weight: 88
Developing NurOwn, an autologous mesenchymal stem cell therapy for ALS, positioning it as a direct competitor in cell-based therapies for ALS, similar to COYA's focus on T-reg cell therapy.
Weight: 85
Clinical-stage biotechnology company singularly focused on developing therapies for a broad range of neurodegenerative diseases, including ALS, Parkinson's, and Alzheimer's, aligning with COYA's disease targets.